Selective Suppressions of Human CYP3A Forms, CYP3A5 and CYP3A7, by Troglitazone in HepG2 Cells

Drug Metabolism and Pharmacokinetics

Volumn 17, Issue 1, 2002, Pages 42-46

  Ogino, Makoto ^a   Nagata, Kiyoshi ^a   Yamazoe, Yasushi ^a  

^a TOHOKU UNIVERSITY   (Japan)

Author keywords

CYP3A5; CYP3A7; HepG2; suppression; transcriptional regulation; troglitazone

Indexed keywords

EID: 29944434772     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.17.42     Document Type: Article

References (21)

1. Gonzalez, F. J.: Human cytochromes P450: problems and prospects. Trends Pharmacol. Sci., 13: 346-352 (1992)
2. Koup, J. R., Anderson, G. D. and Loi, C. M.: Effect of troglitazone on urinary excretion of 6b-hydroxycortisol. J. Clin. Pharmacol., 38: 815-818 (1998).
3. Ramachandran, V., Kostrubsky, V. E., Komoroski, B. J., Zhang, S., Dorko, K., Esplen, J. E., Strom, S. C. and Venkataramanan, R.: Troglitazone increases cytochrome P-450 3A protein and activity in primary cultures of human hepatocytes. Drug Metab. Dispos., 27: 1194-1199 (1999).
4. Schoonjans, K. and Auwerx, J.: Thiazolidinediones: an update. Lancet, 355: 1008-1010 (2000).
5. Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M. and Kliewer, S. A.: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor g (PPARg). J. Biol. Chem., 270: 12953-12956 (1995).
6. Sumida, A., Fukuen, S., Yamamoto, I., Matsuda, H., Naohara, M. and Azuma, J.: Quantitative analysis of constitutive and inducible CYPs mRNA expression in the HepG2 cell line using reverse transcription-competitive PCR. Biochem. Biophys. Res. Commun., 267: 756-760 (2000).
7. Goodwin, B., Hodgson, E. and Liddle, C.: The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol., 56: 1329-1339 (1999).
8. Yao, D., Ding, S., Burchell, B., Wolf, C. R. and Friedberg, T.: Detoxication of vinca alkaloids by human P450 CYP3A4-mediated metabolism: implications for the development of drug resistance. J. Pharmacol. Exp. Ther., 294: 387-395 (2000).
9. Schuetz, J. D., Schuetz, E. G., Thottassery, J. V., Guzelian, P. S., Strom, S. and Sun, D.: Identification of a novel dexamethasone responsive enhancer in the human CYP3A5 gene and its activation in human and rat liver cells. Mol. Pharmacol., 49: 63-72 (1996).
10. Chomczynski, P. and Sacchi, N.: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156-159 (1987).
11. Nagata, K., Ogino, M., Shimada, M., Miyata, M., Gonzalez, F. J. and Yamazoe, Y.: Structure and expression of the rat CYP3A1 gene: isolation of the gene (P450/6 bB) and characterization of the recombinant protein. Arch. Biochem. Biophys., 362: 242-253 (1999).
12. Kawano, S., Kamataki, T., Yasumori, T., Yamazoe, Y. and Kato, R.: Purification of human liver cytochrome P-450 catalyzing testosterone 6b-hydroxylation. J. Biochem. (Tokyo)., 102: 493-501 (1987).
13. Murayama, N., Shimada, M., Yamazoe Y. and Kato, R.: Difference in the susceptibility of two phenobarbital-inducible forms, P450IIB1 and P450IIB2, to thyroid hormone-and growth hormone-induced suppression in rat liver: phenobarbital-inducible P450IIB2 suppression by thyroid hormone acting directly, but not through the pituitary system. Mol. Pharmacol., 39: 811-817 (1991).
14. Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, J. T. and Kliewer, S. A.: The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest., 102: 1016-1023 (1998).
15. Blumberg, B., Sabbagh, W. Jr., Juguilon, H., Bolado, J. Jr., van Meter, C. M., Ong, E. S. and Evans, R. M.: SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Deve., 12: 3195-3205 (1998).
16. Pascussi, J. M., Jounaidi, Y., Drocourt, L., Domergue, J., Balabaud, C., Maurel, P. and Vilarem, M. J.: Evidence for the presence of a functional pregnane X receptor response element in the CYP3A7 promoter gene. Biochem. Biophys. Res. Commun., 260: 377-381 (1999).
17. Camp, H. S., Li, O., Wise, S. C., Hong, Y. H., Frankowski, C. L., Shen, X., Vanbogelen, R. and Leff, T.: Differential activation of peroxisome proliferator-activated receptor-gamma by troglitazone and rosiglitazone. Diabetes, 49: 539-547 (2000).
18. Jones, S. A., Moore, L. B., Shenk, J. L., Wisely, G. B., Hamilton, G. A., McKee, D. D., Tomkinson, N. C., LeCluyse, E. L., Lambert, M. H., Willson, T. M., Kliewer, S. A. and Moore, J. T.: The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol., 14: 27-39 (2000).
19. Jover, R., Bort, R., Gomez-Lechon, M. J. and Castell, J. V.: Cytochrome P450 regulation bv hepatocyte nuclear factor 4 In human hepatocyte: a study using adenovirus-mediated antisense targeting. Hepatology, 33: 668-675 (2001).
20. Fajas, L., Auboeuf, D., Raspe, E., Schoonjans, K., Lefebvre, A. M., Saladin, R., Najib, J., Laville, M., Fruchart, J. C., Deeb, S., Vidal-Puig, A., Flier, J., Briggs, M. R., Staels, B., Vidal, H. and Auwerx, J.: The organization, promoter analysis, and expression of the human PPARg gene. J. Biol. Chem., 272: 18779-18789 (1997).
21. Jover, R., Bort, R., Gomez-Lechon, M. J. and Castell, J. V.: Re-expression of C/EBPa induces CYP2B6, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Lett., 431: 227-230 (1998).